Follow up Study of Patients Having Participated in Clinical Trial 64,185-204
NCT ID: NCT02000830
Last Updated: 2021-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
68 participants
OBSERVATIONAL
2013-10-17
2020-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-Term Clinical Follow-Up of Children Enrolled in Stannsoporfin Clinical Trial Protocol No. 64,185-06-2(W)
NCT02685189
Safety and Pharmacology of Stanate
NCT00115544
Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients
NCT07338344
Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies
NCT03020615
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
NCT05904093
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Reported AEs and SAEs Hearing assessments Developmental assessments
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Participants received placebo during the earlier study
Placebo
Matching placebo administered by IM injection
Stannsoporfin 3.0 mg/kg
Participants received Stannsoporfin 3.0 mg/kg during the earlier study
Stannsoporfin
Stannsoporfin administered by intramuscular (IM) injection
Stannsoporfin 4.5 mg/kg
Participants received Stannsoporfin 4.5 mg/kg during the earlier study
Stannsoporfin
Stannsoporfin administered by intramuscular (IM) injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Stannsoporfin
Stannsoporfin administered by intramuscular (IM) injection
Placebo
Matching placebo administered by IM injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Parents or guardians have given written informed consent to participate
30 Days
52 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Leader, MD
Role: STUDY_CHAIR
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
64,185-205
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.